|
Cosmo Pharmaceuticals N.V.
/ Key word(s): Miscellaneous
Medtronic wins U.S. Department of Veterans Affairs contract to provide GI Genius™ intelligent endoscopy module for artificial intelligence (AI) assisted colon cancer screening
06.10.2022 / 06:15 GMT/BST
Dublin, Ireland – 06 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that Medtronic, its global partner for GI Genius™, published a media release that it has been awarded a contract for its Gastrointestinal Business Unit, through partnership with a Service-Disabled Veteran-Owned Small Businesses (SDVOSB), to install 115 Medtronic GI Genius™ intelligent endoscopy modules at numerous VA medical facilities across the country. Through this contract, veterans will have access to artificial intelligence (AI) technology that has been proven to improve the accuracy of polyp detection in colonoscopy screening.
Alessandro Della Chà, CEO of Cosmo, commented: “Veterans will now have access to GI Genius™ and we congratulate our partner Medtronic on this achievement and for intensively promoting GI Genius™. This contract further highlights the need for GI Genius™ to help prevent colorectal cancer”.
Please read full details in Medtronic’s press release .
| Upcoming Calendar of Events |
|
| Credit Suisse Equity Forum Switzerland |
November 16, 2022 |
| Jefferies 2022 London Healthcare Conference |
November 15-17, 2022 |
| Deutsches Eigenkapitalforum, Frankfurt |
November 28-30, 2022 |
About Cosmo
Cosmo is a pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders, to improve endoscopy quality measures through aiding the detection of colonic lesions and to treat selected dermatological conditions. Cosmo develops and manufactures products which are distributed globally by selected partners including Lialda®, Uceris®/Cortiment® and Winlevi®. Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic for the global distribution of GI Genius™ which uses artificial intelligence to help detect potential signs of colon cancer. Cosmo has licensed Aemcolo® to Red Hill Biopharma Ltd. for the US and has licensed Relafalk® to Dr. Falk Gmbh for the EU and other countries. The company also has a rich development pipeline. For additional information on Cosmo and its products please visit the Company’s website:
Disclaimer
Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Cosmo and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.
Contact:
Cosmo
Hazel Winchester
Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: 0
End of Media Release
|
| Language: |
English |
| Company: |
Cosmo Pharmaceuticals N.V. |
|
Riverside 2, Sir John Rogerson’s |
|
Dublin 2 Dublin |
|
Ireland |
| Phone: |
0 |
| E-mail: |
|
| Internet: |
/ |
| ISIN: |
NL0011832936 |
| Listed: |
SIX Swiss Exchange |
| EQS News ID: |
1457809 |
| |
| End of News |
EQS News Service |
1457809 06.10.2022 GMT/BST
